All sponsors

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. $1801.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-36
RECRUITING5
READOUTS ≤12 MONTHS0
Open Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. on the live radar map → 📅 $1801.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Picankibart
NCT06945107
P3Active, not recruitingPlaque Psoriasis3082026-06-07
IBI112
NCT07265284
P3RecruitingPsoriasis1042026-09-30
Bevacizumab
NCT07490262
P2/3RecruitingHepatocellular Carcinoma (HCC)6802027-12-31
Trastuzumab
NCT07377643
P3RecruitingHER2-positive Breast Cancer5402028-04-28
Picankibart
NCT07295509
P2/3RecruitingPsoriatic Arthritis2222029-12-31
tegafur, Gimeracil and Oteracil Potassium Capsules
NCT07643623
P2/3RecruitingResectable Gastric/Gastroesophageal Junction Adenocarcinoma7202031-12-31